329 related articles for article (PubMed ID: 7737939)
21. [Antibodies to cytomegaloviruses in blood donors].
Courault K; Lissé I; Richter H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):183-6. PubMed ID: 2475395
[TBL] [Abstract][Full Text] [Related]
22. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus infection as a complication of blood transfusion.
Tegtmeier GE
Semin Liver Dis; 1986 Feb; 6(1):82-95. PubMed ID: 3012785
[No Abstract] [Full Text] [Related]
24. Cytomegalovirus and blood transfusion.
Tegtmeier GE
Prog Clin Biol Res; 1985; 182():175-99. PubMed ID: 2994097
[No Abstract] [Full Text] [Related]
25. Transfusion-related cytomegalovirus infection among very low birth weight infants in an endemic area.
Kim AR; Lee YK; Kim KA; Chu YK; Baik BY; Kim ES; Yun SC; Kim KS; Pi SY
J Korean Med Sci; 2006 Feb; 21(1):5-10. PubMed ID: 16479056
[TBL] [Abstract][Full Text] [Related]
26. Indications for the use of cytomegalovirus-seronegative blood products.
Preiksaitis JK
Transfus Med Rev; 1991 Jan; 5(1):1-17. PubMed ID: 1666324
[No Abstract] [Full Text] [Related]
27. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.
Weisberg SP; Staley EM; Williams LA; Pham HP; Bachegowda LS; Cheng YH; Schwartz J; Shaz BH
Arch Pathol Lab Med; 2017 Dec; 141(12):1705-1711. PubMed ID: 28849943
[TBL] [Abstract][Full Text] [Related]
28. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
30. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
31. [Prevention of post-transfusion cytomegalovirus infection: recommendations for clinical practice].
Zwicky C; Tissot JD; Mazouni ZT; Schneider P; Burnand B
Schweiz Med Wochenschr; 1999 Jul; 129(29-30):1061-6. PubMed ID: 10464908
[TBL] [Abstract][Full Text] [Related]
32. Definitions of cytomegalovirus infection and disease in transplant recipients.
Ljungman P; Griffiths P; Paya C
Clin Infect Dis; 2002 Apr; 34(8):1094-7. PubMed ID: 11914998
[TBL] [Abstract][Full Text] [Related]
33. The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients.
Ziemann M; Juhl D; Görg S; Hennig H
Transfusion; 2013 Oct; 53(10):2183-9. PubMed ID: 23581526
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program.
Rossini F; Terruzzi E; Cammarota S; Morini F; Fumagalli M; Verga L; Elli E; Verga M; Miccolis I; Parma M; Pogliani EM
Transpl Infect Dis; 2005; 7(3-4):122-5. PubMed ID: 16390400
[TBL] [Abstract][Full Text] [Related]
35. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood.
Seed CR; Piscitelli LM; Maine GT; Lazzarotto T; Doherty K; Stricker R; Stricker R; Iriarte B; Patel C
Transfusion; 2009 Jan; 49(1):134-45. PubMed ID: 18954407
[TBL] [Abstract][Full Text] [Related]
36. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
Narvios AB; Lichtiger B
Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
[TBL] [Abstract][Full Text] [Related]
37. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
[TBL] [Abstract][Full Text] [Related]
38. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
Roback JD; Conlan M; Drew WL; Ljungman P; Nichols WG; Preiksaitis JK
Transfus Med Rev; 2006 Jan; 20(1):45-56. PubMed ID: 16373187
[TBL] [Abstract][Full Text] [Related]
39. Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections.
Ziemann M; Heuft HG; Frank K; Kraas S; Görg S; Hennig H
Transfusion; 2013 May; 53(5):1088-94. PubMed ID: 23320406
[TBL] [Abstract][Full Text] [Related]
40. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
Voruz S; Gowland P; Eyer C; Widmer N; Abonnenc M; Prudent M; Masouridi-Levrat S; Duchosal MA; Niederhauser C
Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
